NCT06791746View on ClinicalTrials.gov

Compound Staphylococcal Lysostaphin Vs. Chlorhexidine Mouthrinse for Oral Mucositis in Patients Undergoing Allo-HSCT

PHASE3CompletedINTERVENTIONAL
Enrollment

388

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

June 30, 2022

Conditions
Stem Cell Transplant ComplicationsOral Mucositis
Interventions
DRUG

compound Staphylococcal lysostaphin mouthrinse

Lysostaphin is a proteolytic enzyme produced by a specific species of Staphylococcus, uniquely capable of cleaving the cross-linking pentaglycine bridges within the cell walls of Staphylococcus aureus.

DRUG

chlorhexidine mouthrinse

Chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing OM.

Trial Locations (1)

Unknown

Bone marrow transplantation center, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou, China, Hangzhou

All Listed Sponsors
lead

Zhejiang University

OTHER

NCT06791746 - Compound Staphylococcal Lysostaphin Vs. Chlorhexidine Mouthrinse for Oral Mucositis in Patients Undergoing Allo-HSCT | Biotech Hunter | Biotech Hunter